시장보고서
상품코드
1166182

세계의 바이오시밀러 시장 - 규모, 점유율, 동향 분석, 기회, 예측 : 제품별, 적응증별, 유통 채널별, 지역별(2019-2029년)

Biosimilars Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Product ; By Disease Indication ; By Distribution Channel ; By Region,

발행일: | 리서치사: Blueweave Consulting & Research Private Limited | 페이지 정보: 영문 240 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 바이오시밀러 시장 규모는 2022년 288억 8,000만 달러에 이를 것으로 추정되며, 2023년부터 2029년 예측 기간 동안 21.3%의 견조한 CAGR로 성장했으며, 2029년에는 1,153억 9,000만 달러에 이를 것으로 예상됩니다. 시장 성장을 뒷받침하는 주요 요인으로는 전세계에서 만연하고 있는 다양한 만성질환의 치료에서 바이오시밀러가 합리적인 가격인 점, 만성질환의 유병률 상승, 다양한 국가의 바이오시밀러의 최근 규제에 대한 당국 승인 등을 들 수 있습니다. 한편, 신규 진입 기업에 대한 엄격한 정책이나 시장 진입 장벽 등이 시장의 성장을 억제할 가능성이 있습니다.

세계의 바이오시밀러(Biosimilars) 시장을 조사했으며, 시장 개요/시장 규모 및 예측/동향/촉진 요인·억제 요인/제품별·적응증별·유통 채널별·지역별 분석/기업 개요 등 포괄적인 정보를 제공합니다.

목차

제1장 조사 프레임워크

제2장 주요 요약

제3장 세계의 바이오시밀러 시장 통찰

  • 산업 밸류체인 분석
  • DROC 분석
    • 성장 촉진 요인
      • 자가면역질환의 유병률 상승
      • 바이오시밀러의 채택 증가
      • 바이오시밀러의 비용효과 향상
    • 억제 요인
      • 제조의 복잡성
    • 기회
      • 연구개발능력 향상
      • 헬스케어 인프라에 대한 정부 투자 증가
    • 과제
      • 격렬한 경쟁
      • 높은 연구개발비
  • 기술 진보/최근 개발
  • 규제 프레임워크
  • Porter’s Five Forces
    • 공급기업의 협상력
    • 구매자의 협상력
    • 신규 참가업체의 위협
    • 대체품의 위협
    • 경쟁의 심각성

제4장 세계의 바이오시밀러 시장 개요

  • 시장 규모와 예측(2019-2029년)
    • 금액별
  • 시장 점유율과 예측
    • 제품별
      • 모노클로날 항체
      • 인슐린
      • 인터페론
      • 에타넬셉트
      • 글루카곤
      • 칼시토닌
    • 적응증별
      • 자가면역질환
      • 만성 질환
      • 혈액 질환
      • 기타
    • 유통 채널별
      • 병원 약국
      • 소매 약국
      • 온라인 약국
    • 지역별
      • 북미
      • 유럽
      • 아시아 태평양 지역
      • 남미
      • 중동·아프리카

제5장 북미의 바이오시밀러 시장

    • 시장 규모와 예측(2019-2029년)
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 적응증별
    • 유통 채널별
    • 국가별
      • 미국
      • 캐나다

제6장 유럽 바이오시밀러 시장

  • 시장 규모와 예측(2019-2029년)
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 적응증별
    • 유통 채널별
    • 국가별
      • 독일
      • 영국
      • 이탈리아
      • 프랑스
      • 스페인
      • 네덜란드
      • 벨기에
      • 북유럽 국가
      • 기타 유럽

제7장 아시아 태평양 지역의 바이오시밀러 시장

  • 시장 규모와 예측(2019-2029년)
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 적응증별
    • 유통 채널별
    • 국가별
      • 중국
      • 인도
      • 일본
      • 한국
      • 호주 뉴질랜드
      • 인도네시아
      • 말레이시아
      • 싱가포르
      • 필리핀
      • 베트남
      • 기타 아시아 태평양 지역

제8장 남미의 바이오시밀러 시장

  • 시장 규모와 예측(2019-2029년)
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 적응증별
    • 유통 채널별
    • 국가별
      • 브라질
      • 멕시코
      • 아르헨티나
      • 페루
      • 콜롬비아
      • 기타 남미

제9장 중동·아프리카의 바이오시밀러 시장

  • 시장 규모와 예측(2019-2029년)
    • 금액별
  • 시장 점유율과 예측
    • 제품별
    • 적응증별
    • 유통 채널별
    • 국가별
      • 사우디 아라비아
      • 아랍 에미리트 연방
      • 카타르
      • 쿠웨이트
      • 이란
      • 남아프리카
      • 나이지리아
      • 케냐
      • 이집트
      • 모로코
      • 알제리
      • 기타 중동 및 아프리카

제10장 경쟁 상황

  • 주요 기업과 제품 리스트
  • 세계의 바이오시밀러 기업 시장 점유율 분석(2022년)
  • 운영 파라미터별 경쟁 벤치마킹
  • 주요 전략적 전개(합병, 인수, 파트너십 등)

제11장 세계의 바이오시밀러 시장에 대한 COVID-19의 영향

제12장 기업 개요(기업 개요, 재무 매트릭스, 경쟁 상황, 주요 인재, 주요 경쟁, 연락처, 전략적 전망, SWOT 분석)

  • Novartis AG
  • Orion Pharma AB
  • Pfizer Inc.
  • Samsung Bioepis
  • Coherus BioSciences, Inc.
  • Amgen Inc.
  • Eli Lilly and Company.
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Biocon
  • Bayer AG
  • AbbVie Inc.
  • Allergan
  • Dr. Reddy's Laboratories Ltd.
  • Boehringer Ingelheim International GmbH
  • Biogen
  • 기타 유력 기업

제13장 주요 전략적 권장 사항

제14장 조사 방법

LYJ 22.12.15

Global Biosimilars Market Size Zooming to Touch USD 115.4 Billion by 2029

Global biosimilar market size is flourishing owing to various blockbuster biological drugs' patent expirations, price reductions, an increase in the prevalence of chronic diseases, and cost-cutting measures taken by governments and third-party payers.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimates global biosimilars market size at USD 28.88 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global biosimilars market size to grow at a robust CAGR of 21.3% reaching a value of USD 115.39 billion by 2029. The affordability of biosimilars in treating a range of chronic diseases that are widespread among the world's population is what is fueling the growth of the global biosimilars market. Due to the rising prevalence of chronic diseases in the population and the recent regulatory authority approval of numerous biosimilars in numerous countries, it is expected that the adoption of biosimilars will increase quickly. Globally, there is a growing demand for biosimilars as people become more aware of their availability and effectiveness in treating a range of disorders. Since kidney failure, diabetes, cancer, and cardiovascular disease are among the many chronic diseases for which biosimilars are an effective treatment option, the market is expected to grow over the coming years. However, strict policies and market entry barriers for new players are likely to limit global market growth.

Global Biosimilars Market - Overview

A biosimilar is a biologic medical product that is extremely similar to an already-approved biologic. These biosimilars are approved based on their efficacy, quality, safety, and pharmaceutical quality standards, which apply to all biological medicines. Biosimilars are generic versions of biologics that have reached the end of their patent life cycle. The patent expiration of well-known biologics is expected to drive the global biosimilar market. Increased approval and sales of biosimilars have resulted in a significant drop in sales of biologics with stable or growing demand. The global burden of chronic diseases is increasing. The rise in the prevalence of chronic diseases can be attributed largely to the aging population and people's changing lifestyles. Some of the most prevalent chronic diseases include diabetes, hypertension, stroke, respiratory and oral illnesses, obesity, arthritis, and cancer. On the other hand, the treatment of cancer and rheumatoid arthritis with biosimilar monoclonal antibodies is widely used.

Biosimilars are being developed by several biopharmaceutical companies around the world. The global biosimilars market has the potential to expand quickly. A large number of biological drugs are likely to lose their patent protection in the coming years. As a result, lower healthcare costs and government regulatory structure changes are expected to drive the market during the forecast period. The use of monoclonal antibodies to treat COVID-19 has rekindled interest in the biosimilars market. Manufacturers are expanding their research capabilities to develop better immunotherapy drugs. These drugs have the potential to reduce the number of side effects experienced by cancer patients. A positive effect on the market is also being produced by the expansion of insurance coverage for biosimilars.

Opportunity: Increasing government spending on healthcare

The federal government's increased funding could fuel the market's expansion. Additionally, the growth and expansion of the healthcare sector, driven by both public and private actors, particularly in developing economies, will present profitable opportunities for the biosimilars market. The market growth rate is also being supported by the government healthcare facilities' growing acceptance of bioidentical hormone replacement therapy. The introduction of technologically advanced products in hospitals, rising investment in the development of advanced, and increased emphasis on women's health care and the treatment of hormonal imbalances are other factors that have a positive impact on the market growth rate.

Challenge: Expensive research and development of biopharmaceutical products

High costs associated with R&D capabilities, high manufacturing costs, and difficulties associated with medical procedures, on the other hand, are expected to stymie market growth. Furthermore, during the forecast period of 2022-2029, the market is expected to face challenges due to a lack of favorable reimbursement scenarios and technology penetration in developing economies, as well as a lack of definitive approval standards and suitable infrastructure in low- and middle-income countries.

Impact of COVID-19 on Global Biosimilars Market

The COVID-19 outbreak affects several international industries, including the market for biosimilars. Administrative bodies everywhere implemented several measures, including lockdowns and strict social seclusion, to slow the Covid-19 pandemic's rapid spread. The biosimilars market was harmed by the widespread closing of manufacturing facilities in the early stages of the pandemic. The pandemic had a significant negative impact on small and medium-sized businesses, which are the primary technology suppliers to the biosimilars industry. The lockdown measures implemented during the early stages of the epidemic's spread limited the movement of people and goods, which affected the biosimilar market as well.

Global Biosimilars Market - By Distribution Channel

The global biosimilar market is divided into three segments based on distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies. During the forecast period between 2023 and 2029, the retail pharmacies segment is expected to lead the global biosimilars market by distribution channel.

Competitive Landscape

Global biosimilars market is fiercely competitive. Prominent players in global biosimilars market include Novartis AG, Orion Pharma AB, Pfizer Inc., Samsung Bioepis, Coherus BioSciences, Inc., Amgen Inc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck KGaA, Teva Pharmaceutical Industries Ltd., Biocon, Bayer AG, AbbVie Inc., Allergan, Dr. Reddy's Laboratories Ltd., Boehringer Ingelheim International GmbH, and Biogen. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in global biosimilars market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Biosimilars Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Biosimilars Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Biosimilars Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Rising prevalence of autoimmune diseases
      • 3.2.1.2. Increasing adoption of biosimilars
      • 3.2.1.3. Rising cost effectiveness of biosimilars
    • 3.2.2. Restraints
      • 3.2.2.1. Complexities in manufacturing
    • 3.2.3. Opportunity
      • 3.2.3.1. Rising research and development proficiencies
      • 3.2.3.2. Rising government investments on healthcare infrastructure
    • 3.2.4. Challenges
      • 3.2.4.1. Intense Competition
      • 3.2.4.2. High cost of R&D
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Biosimilars Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product
      • 4.2.1.1. Monoclonal Antibodies
      • 4.2.1.1.1. Infliximab
      • 4.2.1.1.2. Rituximab
      • 4.2.1.1.3. Trastuzumab
      • 4.2.1.2. Insulin
      • 4.2.1.3. Interferon
      • 4.2.1.4. Etanercept
      • 4.2.1.5. Glucagon
      • 4.2.1.6. Calcitonin
    • 4.2.2. By Disease Indication
      • 4.2.2.1. Cancer
      • 4.2.2.2. Auto-Immune Diseases
      • 4.2.2.3. Chronic Diseases
      • 4.2.2.4. Blood Disorders
      • 4.2.2.5. Others
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Biosimilars Market

    • 5.1.1. Market Size & Forecast, 2019-2029
    • 5.1.2. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Disease Indication
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Product
      • 5.2.4.1.2. By Disease Indication
      • 5.2.4.1.3. By Distribution Channel
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Product
      • 5.2.4.2.2. By Disease Indication
      • 5.2.4.2.3. By Distribution Channel

6. Europe Biosimilars Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Disease Indication
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Product
      • 6.2.4.1.2. By Disease Indication
      • 6.2.4.1.3. By Distribution Channel
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Product
      • 6.2.4.2.2. By Disease Indication
      • 6.2.4.2.3. By Distribution Channel
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Product
      • 6.2.4.3.2. By Disease Indication
      • 6.2.4.3.3. By Distribution Channel
      • 6.2.4.4. France
      • 6.2.4.4.1. By Product
      • 6.2.4.4.2. By Disease Indication
      • 6.2.4.4.3. By Distribution Channel
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Product
      • 6.2.4.5.2. By Disease Indication
      • 6.2.4.5.3. By Distribution Channel
      • 6.2.4.6. The Netherlands
      • 6.2.4.6.1. By Product
      • 6.2.4.6.2. By Disease Indication
      • 6.2.4.6.3. By Distribution Channel
      • 6.2.4.7. Belgium
      • 6.2.4.7.1. By Product
      • 6.2.4.7.2. By Disease Indication
      • 6.2.4.7.3. By Distribution Channel
      • 6.2.4.8. NORDIC Countries
      • 6.2.4.8.1. By Product
      • 6.2.4.8.2. By Disease Indication
      • 6.2.4.8.3. By Distribution Channel
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Product
      • 6.2.4.9.2. By Disease Indication
      • 6.2.4.9.3. By Distribution Channel

7. Asia Pacific Biosimilars Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Disease Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Product
      • 7.2.4.1.2. By Disease Indication
      • 7.2.4.1.3. By Distribution Channel
      • 7.2.4.2. India
      • 7.2.4.2.1. By Product
      • 7.2.4.2.2. By Disease Indication
      • 7.2.4.2.3. By Distribution Channel
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Product
      • 7.2.4.3.2. By Disease Indication
      • 7.2.4.3.3. By Distribution Channel
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Product
      • 7.2.4.4.2. By Disease Indication
      • 7.2.4.4.3. By Distribution Channel
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Product
      • 7.2.4.5.2. By Disease Indication
      • 7.2.4.5.3. By Distribution Channel
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Product
      • 7.2.4.6.2. By Disease Indication
      • 7.2.4.6.3. By Distribution Channel
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Product
      • 7.2.4.7.2. By Disease Indication
      • 7.2.4.7.3. By Distribution Channel
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Product
      • 7.2.4.8.2. By Disease Indication
      • 7.2.4.8.3. By Distribution Channel
      • 7.2.4.9. Philippines
      • 7.2.4.9.1. By Product
      • 7.2.4.9.2. By Disease Indication
      • 7.2.4.9.3. By Distribution Channel
      • 7.2.4.10. Vietnam
      • 7.2.4.10.1. By Product
      • 7.2.4.10.2. By Disease Indication
      • 7.2.4.10.3. By Distribution Channel
      • 7.2.4.11. Rest of Asia Pacific
      • 7.2.4.11.1. By Product
      • 7.2.4.11.2. By Disease Indication
      • 7.2.4.11.3. By Distribution Channel

8. Latin America Biosimilars Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Disease Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Product
      • 8.2.4.1.2. By Disease Indication
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Product
      • 8.2.4.2.2. By Disease Indication
      • 8.2.4.2.3. By Distribution Channel
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Product
      • 8.2.4.3.2. By Disease Indication
      • 8.2.4.3.3. By Distribution Channel
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Product
      • 8.2.4.4.2. By Disease Indication
      • 8.2.4.4.3. By Distribution Channel
      • 8.2.4.5. Colombia
      • 8.2.4.5.1. By Product
      • 8.2.4.5.2. By Disease Indication
      • 8.2.4.5.3. By Distribution Channel
      • 8.2.4.6. Rest of Latin America
      • 8.2.4.6.1. By Product
      • 8.2.4.6.2. By Disease Indication
      • 8.2.4.6.3. By Distribution Channel

9. Middle East & Africa Biosimilars Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Disease Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Product
      • 9.2.4.1.2. By Disease Indication
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Product
      • 9.2.4.2.2. By Disease Indication
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Product
      • 9.2.4.3.2. By Disease Indication
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Product
      • 9.2.4.4.2. By Disease Indication
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Iran
      • 9.2.4.5.1. By Product
      • 9.2.4.5.2. By Disease Indication
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. South Africa
      • 9.2.4.6.1. By Product
      • 9.2.4.6.2. By Disease Indication
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Nigeria
      • 9.2.4.7.1. By Product
      • 9.2.4.7.2. By Disease Indication
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. Kenya
      • 9.2.4.8.1. By Product
      • 9.2.4.8.2. By Disease Indication
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Egypt
      • 9.2.4.9.1. By Product
      • 9.2.4.9.2. By Disease Indication
      • 9.2.4.9.3. By Distribution Channel
      • 9.2.4.10. Morocco
      • 9.2.4.10.1. By Product
      • 9.2.4.10.2. By Disease Indication
      • 9.2.4.10.3. By Distribution Channel
      • 9.2.4.11. Algeria
      • 9.2.4.11.1. By Product
      • 9.2.4.11.2. By Disease Indication
      • 9.2.4.11.3. By Distribution Channel
      • 9.2.4.12. Rest of Middle East & Africa
      • 9.2.4.12.1. By Product
      • 9.2.4.12.2. By Disease Indication
      • 9.2.4.12.3. By Distribution Channel

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Biosimilars Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, and others)

11. Impact of Covid-19 on Global Biosimilars Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Novartis AG
  • 12.2. Orion Pharma AB
  • 12.3. Pfizer Inc.
  • 12.4. Samsung Bioepis
  • 12.5. Coherus BioSciences, Inc.
  • 12.6. Amgen Inc.
  • 12.7. Eli Lilly and Company.
  • 12.8. Takeda Pharmaceutical Company Limited
  • 12.9. Bristol-Myers Squibb Company
  • 12.10. Merck KGaA
  • 12.11. Teva Pharmaceutical Industries Ltd.
  • 12.12. Biocon
  • 12.13. Bayer AG
  • 12.14. AbbVie Inc.
  • 12.15. Allergan
  • 12.16. Dr. Reddy's Laboratories Ltd.
  • 12.17. Boehringer Ingelheim International GmbH
  • 12.18. Biogen
  • 12.19. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제